Koutif Therapeutics’ KT-1002 Reaches Clinical Candidate Status

Koutif Therapeutics announces that KT-1002, which has been selected as its lead compound, has reached clinical candidate status for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohns Disease, after successfully completing IND-enabling studies.

Read More  >